Receptors, Progesterone

"Receptors, Progesterone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.

Descriptor ID	D011980
MeSH Number(s)	D12.776.826.750.765
Concept/Terms	Receptors, Progesterone Receptors, Progesterone Progesterone Receptor Receptor, Progesterone Progestin Receptors Receptors, Progestin Progesterone Receptors

Below are MeSH descriptors whose meaning is more general than "Receptors, Progesterone".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Receptors, Cytoplasmic and Nuclear [D12.776.826]
Receptors, Steroid [D12.776.826.750]
Receptors, Progesterone [D12.776.826.750.765]

Below are MeSH descriptors whose meaning is related to "Receptors, Progesterone".

Below are MeSH descriptors whose meaning is more specific than "Receptors, Progesterone".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Receptors, Progesterone" by people in this website by year, and whether "Receptors, Progesterone" was a major or minor topic of these publications.

Bar chart showing 79 publications over 24 distinct years, with a maximum of 10 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
2000	1	0	1
2001	0	1	1
2002	0	2	2
2005	1	2	3
2006	3	1	4
2007	2	3	5
2008	1	0	1
2009	2	1	3
2010	3	1	4
2011	3	7	10
2012	0	5	5
2013	1	2	3
2014	1	2	3
2015	1	3	4
2016	0	3	3
2017	2	6	8
2018	0	3	3
2019	1	4	5
2020	0	3	3
2021	0	4	4
2022	0	1	1
2023	0	1	1
2024	1	0	1

Below are the most recent publications written about "Receptors, Progesterone" by people in Profiles.

Mayer EL, Ren Y, Wagle N, Mahtani R, Ma C, DeMichele A, Cristofanilli M, Meisel J, Miller KD, Abdou Y, Riley EC, Qamar R, Sharma P, Reid S, Sinclair N, Faggen M, Block CC, Ko N, Partridge AH, Chen WY, DeMeo M, Attaya V, Okpoebo A, Alberti J, Liu Y, Gauthier E, Burstein HJ, Regan MM, Tolaney SM. PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. J Clin Oncol. 2024 06 10; 42(17):2050-2060.

View in: PubMed
Lee YJ, Yoo TK, Kim J, Chung IY, Ko BS, Kim HJ, Lee JW, Son BH, Ahn SH, Lee SB. Survival outcomes of breast cancer patients with recurrence after surgery according to period and subtype. PLoS One. 2023; 18(7):e0284460.

View in: PubMed
Matar R, Barrio AV, Sevilimedu V, Le T, Heerdt A, Morrow M, Tadros A. Can We Successfully De-Escalate Axillary Surgery in Women Aged = 70 Years with Ductal Carcinoma in Situ or Early-Stage Breast Cancer Undergoing Mastectomy? Ann Surg Oncol. 2022 Apr; 29(4):2263-2272.

View in: PubMed
Lee YJ, Hwang YS, Kim J, Ahn SH, Son BH, Kim HJ, Ko BS, Kim J, Chung IY, Lee JW, Lee SB. A nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer. Sci Rep. 2021 12 06; 11(1):23509.

View in: PubMed
Gong Y, Nagarathinam R, Arisi MF, Gerratana L, Winn JS, Slifker M, Pei J, Cai KQ, Hasse Z, Obeid E, Noriega J, Sebastiano C, Ross E, Alpaugh K, Cristofanilli M, Fernandez SV. Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC). Int J Mol Sci. 2021 Aug 19; 22(16).

View in: PubMed
DeMichele A, Cristofanilli M, Brufsky A, Liu X, Mardekian J, McRoy L, Layman RM, Emir B, Torres MA, Rugo HS, Finn RS. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Res. 2021 03 24; 23(1):37.

View in: PubMed
Albinsaad LS, Kim J, Chung IY, Ko BS, Kim HJ, Lee JW, Son BH, Ahn SH, Lee SB. Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy. Breast Cancer Res Treat. 2021 Jun; 187(2):447-454.

View in: PubMed
Kim HJ, Noh WC, Lee ES, Jung YS, Kim LS, Han W, Nam SJ, Gong G-, Kim HJ, Ahn SH. Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer. Breast Cancer Res. 2020 05 27; 22(1):54.

View in: PubMed
Ettl J, Im SA, Ro J, Masuda N, Colleoni M, Schnell P, Bananis E, Lu DR, Cristofanilli M, Rugo HS, Finn RS. Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. Breast Cancer Res. 2020 03 12; 22(1):27.

View in: PubMed
Shah AN, Flaum L, Helenowski I, Santa-Maria CA, Jain S, Rademaker A, Nelson V, Tsarwhas D, Cristofanilli M, Gradishar W. Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer. J Immunother Cancer. 2020 02; 8(1).

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement